Mutation-specific CAR T cells as precision therapy for IGLV3-21
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
02 Feb 2024
02 Feb 2024
Historique:
received:
05
12
2023
accepted:
22
01
2024
medline:
3
2
2024
pubmed:
3
2
2024
entrez:
2
2
2024
Statut:
epublish
Résumé
The concept of precision cell therapy targeting tumor-specific mutations is appealing but requires surface-exposed neoepitopes, which is a rarity in cancer. B cell receptors (BCR) of mature lymphoid malignancies are exceptional in that they harbor tumor-specific-stereotyped sequences in the form of point mutations that drive self-engagement of the BCR and autologous signaling. Here, we use a BCR light chain neoepitope defined by a characteristic point mutation (IGLV3-21
Identifiants
pubmed: 38307904
doi: 10.1038/s41467-024-45378-w
pii: 10.1038/s41467-024-45378-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
993Subventions
Organisme : Deutsche Forschungsgemeinschaft (German Research Foundation)
ID : BI 1711/4-1
Informations de copyright
© 2024. The Author(s).
Références
Stamatopoulos, K. et al. Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: pathogenetic implications and clinical correlations. Blood 109, 259–270 (2007).
pubmed: 16985177
doi: 10.1182/blood-2006-03-012948
Binder, M. et al. B-cell receptor epitope recognition correlates with the clinical course of chronic lymphocytic leukemia. Cancer 117, 1891–1900 (2011).
pubmed: 21509766
doi: 10.1002/cncr.25755
Gomes de Castro, M. A. et al. Differential organization of tonic and chronic B cell antigen receptors in the plasma membrane. Nat. Commun. 10, 820 (2019).
pubmed: 30778055
pmcid: 6379438
doi: 10.1038/s41467-019-08677-1
Duhren-von Minden, M. et al. Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling. Nature 489, 309–312 (2012).
pubmed: 22885698
doi: 10.1038/nature11309
Hallek, M. et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood 131, 2745–2760 (2018).
pubmed: 29540348
doi: 10.1182/blood-2017-09-806398
Nadeu, F. et al. IGLV3-21R110 identifies an aggressive biological subtype of chronic lymphocytic leukemia with intermediate epigenetics. Blood 137, 2935–2946 (2021).
pubmed: 33211804
pmcid: 8191863
doi: 10.1182/blood.2020008311
Brudno, J. N. et al. Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease. J. Clin. Oncol. 34, 1112–1121 (2016).
pubmed: 26811520
pmcid: 4872017
doi: 10.1200/JCO.2015.64.5929
Todorovic, Z. et al. CAR T cell therapy for chronic lymphocytic leukemia: successes and shortcomings. Curr. Oncol. 29, 3647–3657 (2022).
pubmed: 35621683
pmcid: 9139644
doi: 10.3390/curroncol29050293
Porter, D. L. et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci. Transl. Med. 7, 303ra139 (2015).
pubmed: 26333935
pmcid: 5909068
doi: 10.1126/scitranslmed.aac5415
Gauthier, J. et al. Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure. Blood 135, 1650–1660 (2020).
pubmed: 32076701
pmcid: 7205814
doi: 10.1182/blood.2019002936
Gill, S. et al. Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia. Blood Adv. 6, 5774–5785 (2022).
pubmed: 35349631
pmcid: 9647791
doi: 10.1182/bloodadvances.2022007317
Evans, A. G. et al. Evolution to plasmablastic lymphoma evades CD19-directed chimeric antigen receptor T cells. Br. J. Haematol. 171, 205–209 (2015).
pubmed: 26084925
doi: 10.1111/bjh.13562
Siddiqi, T. et al. Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL. Blood 139, 1794–1806 (2022).
pubmed: 34699592
doi: 10.1182/blood.2021011895
Maity, P. C. et al. IGLV3-21*01 is an inherited risk factor for CLL through the acquisition of a single-point mutation enabling autonomous BCR signaling. Proc. Natl Acad. Sci. USA 117, 4320–4327 (2020).
pubmed: 32047037
pmcid: 7049113
doi: 10.1073/pnas.1913810117
Minici, C. et al. Distinct homotypic B-cell receptor interactions shape the outcome of chronic lymphocytic leukaemia. Nat. Commun. 8, 15746 (2017).
pubmed: 28598442
pmcid: 5472768
doi: 10.1038/ncomms15746
Stamatopoulos, B. et al. The light chain IgLV3-21 defines a new poor prognostic subgroup in chronic lymphocytic leukemia: results of a multicenter study. Clin. Cancer Res. 24, 5048–5057 (2018).
pubmed: 29945996
doi: 10.1158/1078-0432.CCR-18-0133
Stamatopoulos, K. et al. Immunoglobulin light chain repertoire in chronic lymphocytic leukemia. Blood 106, 3575–3583 (2005).
pubmed: 16076869
doi: 10.1182/blood-2005-04-1511
Kostareli, E. et al. Intraclonal diversification of immunoglobulin light chains in a subset of chronic lymphocytic leukemia alludes to antigen-driven clonal evolution. Leukemia 24, 1317–1324 (2010).
pubmed: 20463750
doi: 10.1038/leu.2010.90
Agathangelidis, A. et al. Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies. Blood 119, 4467–4475 (2012).
pubmed: 22415752
pmcid: 3392073
doi: 10.1182/blood-2011-11-393694
Agathangelidis, A. et al. Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL. Blood 137, 1365–1376 (2021).
pubmed: 32992344
pmcid: 7976441
doi: 10.1182/blood.2020007039
Gemenetzi, K. et al. Higher-order immunoglobulin repertoire restrictions in CLL: the illustrative case of stereotyped subsets 2 and 169. Blood 137, 1895–1904 (2021).
pubmed: 33036024
doi: 10.1182/blood.2020005216
Baeuerle, P. A. et al. Synthetic TRuC receptors engaging the complete T cell receptor for potent anti-tumor response. Nat. Commun. 10, 2087 (2019).
pubmed: 31064990
pmcid: 6504948
doi: 10.1038/s41467-019-10097-0
Markl, F. et al. Bispecific antibodies redirect synthetic agonistic receptor modified T cells against melanoma. J. Immunother. Cancer 11, e006436 (2023).
pubmed: 37208128
pmcid: 10201273
doi: 10.1136/jitc-2022-006436
Benmebarek, M. R. et al. A modular and controllable T cell therapy platform for acute myeloid leukemia. Leukemia 35, 2243–2257 (2021).
pubmed: 33414484
pmcid: 7789085
doi: 10.1038/s41375-020-01109-w
Long, A. H. et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat. Med. 21, 581–590 (2015).
pubmed: 25939063
pmcid: 4458184
doi: 10.1038/nm.3838
Ying, Z. et al. Parallel comparison of 4-1BB or CD28 co-stimulated CD19-targeted CAR-T cells for B cell non-Hodgkin’s Lymphoma. Mol. Ther. Oncolytics 15, 60–68 (2019).
pubmed: 31650026
pmcid: 6804784
doi: 10.1016/j.omto.2019.08.002
Festag, M. M. et al. Evaluation of a fully human, Hepatitis B virus-specific chimeric antigen receptor in an immunocompetent mouse model. Mol. Ther. 27, 947–959 (2019).
pubmed: 30852138
pmcid: 6520494
doi: 10.1016/j.ymthe.2019.02.001
Meixlsperger, S. et al. Conventional light chains inhibit the autonomous signaling capacity of the B cell receptor. Immunity 26, 323–333 (2007).
pubmed: 17331747
doi: 10.1016/j.immuni.2007.01.012
Paschold, L. et al. Subclonal heterogeneity sheds light on the transformation trajectory in IGLV3-21R110 chronic lymphocytic leukemia. Blood Cancer J. 12, 49 (2022).
pubmed: 35354800
pmcid: 8969164
doi: 10.1038/s41408-022-00650-4
Maude, S. L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507–1517 (2014).
pubmed: 25317870
pmcid: 4267531
doi: 10.1056/NEJMoa1407222
Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 378, 439–448 (2018).
pubmed: 29385370
pmcid: 5996391
doi: 10.1056/NEJMoa1709866
June, C. H., O’Connor, R. S., Kawalekar, O. U., Ghassemi, S. & Milone, M. C. CAR T cell immunotherapy for human cancer. Science 359, 1361–1365 (2018).
pubmed: 29567707
doi: 10.1126/science.aar6711
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A. & June, C. H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725–733 (2011).
pubmed: 21830940
pmcid: 3387277
doi: 10.1056/NEJMoa1103849
Rosenbaum, L. Tragedy, perseverance, and chance - the story of CAR-T therapy. N. Engl. J. Med. 377, 1313–1315 (2017).
pubmed: 28902570
doi: 10.1056/NEJMp1711886
Park, J. H. et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N. Engl. J. Med. 378, 449–459 (2018).
pubmed: 29385376
pmcid: 6637939
doi: 10.1056/NEJMoa1709919
Mackensen, A. et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat. Med. 28, 2124–2132 (2022).
pubmed: 36109639
doi: 10.1038/s41591-022-02017-5
Haghikia, A. et al. Anti-CD19 CAR T cells for refractory myasthenia gravis. Lancet Neurol. 22, 1104–1105 (2023).
pubmed: 37977704
doi: 10.1016/S1474-4422(23)00375-7
Shah, N. N. & Fry, T. J. Mechanisms of resistance to CAR T cell therapy. Nat. Rev. Clin. Oncol. 16, 372–385 (2019).
pubmed: 30837712
pmcid: 8214555
Zola, H. et al. Preparation and characterization of a chimeric CD19 monoclonal antibody. Immunol. Cell Biol. 69, 411–422 (1991).
pubmed: 1725979
doi: 10.1038/icb.1991.58
Sommermeyer, D. et al. Fully human CD19-specific chimeric antigen receptors for T-cell therapy. Leukemia 31, 2191–2199 (2017).
pubmed: 28202953
pmcid: 5608623
doi: 10.1038/leu.2017.57
Maus, M. V. et al. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol. Res. 1, 26–31 (2013).
pubmed: 24777247
pmcid: 3888798
doi: 10.1158/2326-6066.CIR-13-0006
Lamers, C. H. et al. Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells. Blood 117, 72–82 (2011).
pubmed: 20889925
doi: 10.1182/blood-2010-07-294520
Kershaw, M. H. et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res. 12, 6106–6115 (2006).
pubmed: 17062687
pmcid: 2154351
doi: 10.1158/1078-0432.CCR-06-1183
Kalos, M. et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med. 3, 95ra73 (2011).
pubmed: 21832238
pmcid: 3393096
doi: 10.1126/scitranslmed.3002842
Frey, N. V. et al. Long-term outcomes from a randomized dose optimization study of chimeric antigen receptor modified T cells in relapsed chronic lymphocytic leukemia. J. Clin. Oncol. 38, 2862–2871 (2020).
pubmed: 32298202
pmcid: 8265376
doi: 10.1200/JCO.19.03237
Siddiqi, T. et al. Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1–2 study. Lancet 402, 641–654 (2023).
pubmed: 37295445
doi: 10.1016/S0140-6736(23)01052-8
Patten, P. E. M. et al. A detailed analysis of parameters supporting the engraftment and growth of chronic lymphocytic leukemia cells in immune-deficient mice. Front. Immunol. 12, 627020 (2021).
pubmed: 33767698
pmcid: 7985329
doi: 10.3389/fimmu.2021.627020
Bertilaccio, M. T. et al. Xenograft models of chronic lymphocytic leukemia: problems, pitfalls and future directions. Leukemia 27, 534–540 (2013).
pubmed: 23041721
doi: 10.1038/leu.2012.268
Chen, S. S. & Chiorazzi, N. Murine genetically engineered and human xenograft models of chronic lymphocytic leukemia. Semin Hematol. 51, 188–205 (2014).
pubmed: 25048783
doi: 10.1053/j.seminhematol.2014.05.001
Ten Hacken, E. & Wu, C. J. Understanding CLL biology through mouse models of human genetics. Blood 138, 2621–2631 (2021).
pubmed: 34940815
pmcid: 8703365
doi: 10.1182/blood.2021011993
Shaw, L. C. et al. TCRvbeta-CART therapy mediates high-precision targeting of malignant T-cell clones. Blood Adv. 7, 1885–1898 (2023).
pubmed: 36053778
doi: 10.1182/bloodadvances.2022008798
Xie, G. et al. CAR-T cells targeting a nucleophosmin neoepitope exhibit potent specific activity in mouse models of acute myeloid leukaemia. Nat. Biomed. Eng. 5, 399–413 (2021).
pubmed: 33046866
doi: 10.1038/s41551-020-00625-5
Ellebrecht, C. T. et al. Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease. Science 353, 179–184 (2016).
pubmed: 27365313
pmcid: 5343513
doi: 10.1126/science.aaf6756
Oberle, A. et al. Monitoring multiple myeloma by next-generation sequencing of V(D)J rearrangements from circulating myeloma cells and cell-free myeloma DNA. Haematologica 102, 1105–1111 (2017).
pubmed: 28183851
pmcid: 5451343
doi: 10.3324/haematol.2016.161414
Paschold, L. et al. SARS-CoV-2-specific antibody rearrangements in prepandemic immune repertoires of risk cohorts and patients with COVID-19. J. Clin. Invest. 131, e142966 (2021).
pubmed: 33064671
pmcid: 7773397
doi: 10.1172/JCI142966
Paschold, L. et al. Evolutionary clonal trajectories in nodular lymphocyte predominant Hodgkin lymphoma with high transformation risk. Haematologica 106, 2654–2666 (2021).
pubmed: 33882641
pmcid: 8485677
doi: 10.3324/haematol.2021.278427
Schieferdecker, A. et al. A transplant “immunome” screening platform defines a targetable epitope fingerprint of multiple myeloma. Blood 127, 3202–3214 (2016).
pubmed: 27034429
doi: 10.1182/blood-2015-10-676536
Schliffke, S. et al. Clinical response to ibrutinib is accompanied by normalization of the T-cell environment in CLL-related autoimmune cytopenia. Leukemia 30, 2232–2234 (2016).
pubmed: 27220665
doi: 10.1038/leu.2016.157
Schultheiß, C. et al. Next-generation sequencing of T and B cell receptor repertoires from COVID-19 patients showed signatures associated with severity of disease. Immunity 53, 442–455.e444 (2020).
pubmed: 32668194
pmcid: 7324317
doi: 10.1016/j.immuni.2020.06.024
Schultheiss, C. et al. Next-generation immunosequencing reveals pathological T-cell architecture in autoimmune hepatitis. Hepatology 73, 1436–1448 (2021).
pubmed: 32692457
doi: 10.1002/hep.31473
Simnica, D., Ittrich, H., Bockemeyer, C., Stein, A. & Binder, M. Targeting the mutational landscape of bystander cells: drug-promoted blood cancer from high-prevalence pre-neoplasias in patients on BRAF inhibitors. Front. Oncol. 10, 540030 (2020).
pubmed: 33042833
pmcid: 7517330
doi: 10.3389/fonc.2020.540030
Thiele, B. et al. Next-generation sequencing of peripheral B-lineage cells pinpoints the circulating clonotypic cell pool in multiple myeloma. Blood 123, 3618–3621 (2014).
pubmed: 24753536
doi: 10.1182/blood-2014-02-556746
van Dongen, J. J. M. et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 concerted action BMH4-CT98-3936. Leukemia 17, 2257–2317 (2003).
pubmed: 14671650
doi: 10.1038/sj.leu.2403202
Bolotin, D. A. et al. MiXCR: software for comprehensive adaptive immunity profiling. Nat. Methods 12, 380–381 (2015).
pubmed: 25924071
doi: 10.1038/nmeth.3364
Giudicelli, V., Chaume, D. & Lefranc, M. P. IMGT/GENE-DB: a comprehensive database for human and mouse immunoglobulin and T cell receptor genes. Nucleic Acids Res. 33, D256–D261 (2005).
pubmed: 15608191
doi: 10.1093/nar/gki010
Karches, C. H. et al. Bispecific antibodies enable synthetic agonistic receptor-transduced T cells for tumor immunotherapy. Clin. Cancer Res. 25, 5890–5900 (2019).
pubmed: 31285373
pmcid: 7611266
doi: 10.1158/1078-0432.CCR-18-3927
Tintelnot, J. et al. Nanobody targeting of epidermal growth factor receptor (EGFR) ectodomain variants overcomes resistance to therapeutic EGFR Antibodies. Mol. Cancer Ther. 18, 823–833 (2019).
pubmed: 30824613
doi: 10.1158/1535-7163.MCT-18-0849
Hudecek, M. et al. The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. Cancer Immunol. Res. 3, 125–135 (2015).
pubmed: 25212991
doi: 10.1158/2326-6066.CIR-14-0127
Rees Smith, B., Sanders, J., Evans, M., Tagami, T. & Furmaniak, J. TSH receptor - autoantibody interactions. Horm. Metab. Res. 41, 448–455 (2009).
pubmed: 19530271
doi: 10.1055/s-0029-1220913
Wang, X. et al. A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood 118, 1255–1263 (2011).
pubmed: 21653320
pmcid: 3152493
doi: 10.1182/blood-2011-02-337360
Weber, K., Bartsch, U., Stocking, C. & Fehse, B. A multicolor panel of novel lentiviral “gene ontology” (LeGO) vectors for functional gene analysis. Mol. Ther. 16, 698–706 (2008).
pubmed: 18362927
doi: 10.1038/mt.2008.6
Ghani, K. et al. Efficient human hematopoietic cell transduction using RD114- and GALV-pseudotyped retroviral vectors produced in suspension and serum-free media. Hum. Gene Ther. 20, 966–974 (2009).
pubmed: 19453219
pmcid: 2861952
doi: 10.1089/hum.2009.001
Prommersberger, S., Hudecek, M. & Nerreter, T. Antibody-based CAR T cells produced by lentiviral transduction. Curr. Protoc. Immunol. 128, e93 (2020).
pubmed: 32150338
doi: 10.1002/cpim.93
Hartl, F. A. et al. Noncanonical binding of Lck to CD3epsilon promotes TCR signaling and CAR function. Nat. Immunol. 21, 902–913 (2020).
pubmed: 32690949
doi: 10.1038/s41590-020-0732-3